**SWOG ASCO ABSTRACTS 2018**

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| **Study** | **Abstract Title/Citation/Abstract Link** | **Authors** | **Number** | **Session Time & Place** |
| **SWOG-LED STUDIES** | | | | |
| S0800 | Immune profiling of pre- and post-treatment breast cancer tissues from the SWOG S0800 randomized neoadjuvant trial of weekly nab-paclitaxel with or without bevacizumab and dose dense doxorubicin and cyclophosphamide.  <http://abstracts.asco.org/214/AbstView_214_213751.html> | Xiaoting Li, Sarah Warren, Vasiliki Pelekanou, Vikram Wali, Mingdong Liu, Patrick Danaher, Nate Elliott, William Barlow, Zeina Nahleh, Christos Hatzis, Lajos Pusztai | Poster Board: #70 • Abstract 578 | Session: Breast Cancer—Local/Regional/Adjuvant  Type: POSTER SESSION  Time: Sat, Jun 02, 8:00 AM - 11:30 AM  Location: Hall A |
| S0812 | Randomized Double-Blind Placebo-Controlled Biomarker Modulation Study of Vitamin D in Premenopausal Women at High Risk for Breast Cancer (SWOG S0812).  <http://abstracts.asco.org/214/AbstView_214_213453.html> | Katherine D. Crew, Garnet Anderson, Dawn L. Hershman, Mary Beth Terry, Danika Lew, Monica Yee, Eric A. Brown, Sebastien S. Kairouz, Lori M. Minasian, Leslie Ford, Banu Arun, Marian Neuhouser, Powel H. Brown | Poster Board: #121 • Abstract 1550 | Session: Cancer Prevention, Hereditary Genetics, and Epidemiology  Type: POSTER SESSION  Time: Sat, Jun 02, 1:15 PM - 4:45 PM  Location: Hall A |
| S0905 | SWOG S0905: A randomized Phase II Study of Cediranib versus Placebo in Combination with Cisplatin and Pemetrexed in Chemonaive Patients with Malignant Pleural Mesothelioma.  <http://abstracts.asco.org/214/AbstView_214_218589.html> | Anne Tsao, Jeiling Miao, Ignacio Wistuba, Nicholas Vogelzang, John Heymach, Frank Fossella, Charles Lu, Mario Velasco, Jr, Brandy Box-Noriega, James Hueftle, Shirish Gadgeel, Mary Redman, David Gandara, Karen Kelly | Poster Board: #121 • Abstract 1550 | Session: Cancer Prevention, Hereditary Genetics, and Epidemiology  Type: POSTER SESSION  Time: Sat, Jun 02, 1:15 PM - 4:45 PM  Location: Hall A |
| S0927 | Omega-3 fatty acid use for obese breast cancer patients  with aromatase inhibitor-related arthralgia (SWOG S0927).  <http://abstracts.asco.org/214/AbstView_214_221581.html> | Sherry Shen, Joseph Unger, Katherine Crew, Cathee Till, Heather Greenlee, Julie Gralow, Shaker Dakhil, Lori M. Minasian, James L. Wade, III, Michael Fisch, N Lynn Henry, Dawn L. Hershman | Abstract  10000 | Session: Patient and Survivor  Care  Type: ORAL ABSTRACT  SESSION  Time: Sun, Jun 03, 8:00-8:12 AM  Location: ORAL ABSTRACT SESSION |
| S1204 | Prevalence of HIV, Hepatitis B Virus (HBV), and Hepatitis C Virus (HCV) Among Newly Diagnosed Cancer Patients Treated in Academic and Community Oncology Practices: SWOG S1204.  <http://abstracts.asco.org/214/AbstView_214_229321.html> | Scott Ramsey, Joseph Unger, Laurence Baker, Richard Little, Rohit Loomba, Jessica Hwang, Rashmi Chugh, Monica Konerman, Kathryn Arnold, Dawn L Hershman | Poster Board: #425 • Abstract 6600 | Session: Health Services Research, Clinical Informatics, and Quality of Care  Type: POSTER SESSION  Time: Sat, Jun 02, 1:15 PM - 4:45 PM  Location: Hall A |
| S1304 | Low vs high dose carfilzomib (Cfz) with dexamethasone (Dex) for relapsed/refractory multiple myeloma (RRMM): Results of SWOG S1304.  <http://abstracts.asco.org/214/AbstView_214_221081.html> | Sikander Ailawadhi, Rachael Sexton, Suzanne Lentzsch, Muneer Abidi, Peter Voorhees, Adam Cohen, Eric Rohren, Stephen Heitner, Kelly Kelly, Niklas Mackler, David Baer, Antje Hoering, Brian G.M. Durie, Robert Z. Orlowski | Poster Board: #24 • Abstract 8015 | Session: Hematologic Malignancies—Plasma Cell Dyscrasia  Type: POSTER DISCUSSION SESSION  Time: Mon, Jun 04, 8:00 AM - 11:30 AM; Discussed at the Poster Discussion Session 3:00 PM - 4:15 PM, at E450  Location: Hall A |
| S1400 | First comprehensive report of impact of genomic alterations, chemotherapy, targeted therapy and immunotherapy on outcomes in the genomics driven squamous master protocol LungMAP.  <http://abstracts.asco.org/214/AbstView_214_219029.html> | Vassiliki Papadimitrakopoulou,  Mary Redman, David Gandara,  Fred R. Hirsch, Philip C. Mack,  Corey Langer, Martin Edelman,  Charu Aggarwal, Mark Socinski,  Scott Gettinger, Saiama Naheed  Waqar, Katie Griffin, Natasha  Leighl, Taofeek Owonikoko,  Jeffrey D. Bradley, Suresh S.  Ramalingam, Thomas  Stinchcombe, Charles Blanke,  Karen Kelly, Roy S. Herbst | Poster  Board:  #342 •  Abstract  9019 | Session: Lung Cancer—Non-  Small Cell Metastatic  Type: POSTER DISCUSSION  SESSION  Time: Sun, Jun 03, 8-11:30 AM;  Discussed 11:30 AM - 12:45 PM,  at Arie Crown Theater  Location: Hall AHH |
| S1400/  S1400G | Prevalence and prognosis of DNA repair deficiency in  squamous cell carcinoma (SCC) patients enrolled on the  S1400 LungMAP study.  <http://abstracts.asco.org/214/AbstView_214_230299.html> | Taofeek Kunle Owonikoko, Mary  Redman, Lauren A. Byers, Katie  Griffin, Fred R. Hirsch, Philip C.  Mack, David R. Gandara,  Jeffrey D. Bradley, Thomas E.  Stinchcombe, Karen Kelly,  Suresh S. Ramalingam, Roy S.  Herbst, Vassiliki  Papadimitrakopoulou | Poster  Board:  #378 •  Abstract  9055 | Session: Lung Cancer—Non-  Small Cell Metastatic  Type: POSTER SESSION  Time: Sun, Jun 03, 8-11:30 AM  Location: Hall A |
| S1505 | SWOG S1505: A Randomized Phase II Study of Perioperative mFOLFIRINOX vs. Gemcitabine/nab-Paclitaxel as Therapy for Resectable Pancreatic Adenocarcinoma.  <http://abstracts.asco.org/214/AbstView_214_219891.html> | Davendra Sohal, Shannon L McDonough, Syed A. Ahmad, Namita Gandhi, Muhammad Shaalan Beg, Andrea Wang-Gillam, Katherine Guthrie, Andrew M. Lowy, Philip Agop Philip, Howard S. Hochster | Poster Board: #331a • Abstract TPS4153 | Session: Gastrointestinal (Noncolorectal) Cancer  Type: POSTER SESSION  Time: Sun, Jun 03, 8- 11:30 AM  Location: Hall A |
| S1512 | SWOG S1512: A phase II and pilot trial of PD-1 blockade with pembrolizumab in patients with resectable or unresectable desmoplastic melanoma (DM).  <http://abstracts.asco.org/214/AbstView_214_212259.html> | Kari Kendra, James Moon, Siwen Hu-Lieskovan, William Carson III, Danae Campos, Michael, Alistair Cochran , Antoni Ribas | Poster Board: #331a • Abstract TPS4153 | Session: Gastrointestinal (Noncolorectal) Cancer  Type: POSTER SESSION  Time: Sun, Jun 03, 8-11:30 AM  Location: Hall A |
| S1607 | Clinical Trial in Progress: Reversing resistance to PD-1 blockade by combination of talimogene laherparepvec (T-VEC) with pembrolizumab (pembro) in advanced melanoma patients following progression on a prior PD-1 inhibitor: SWOG S1607 (NCT#02965716).  <http://abstracts.asco.org/214/AbstView_214_221999.html> | Siwen Hu-Lieskovan, James Moon, Ann M. Lau Clark, Kenneth Grossmann, Jeffrey Sosman, Danae Compos, Michael C. Wu, Christopher Ryan, Antoni Ribas | Poster Board: #426a • Abstract TPS9603 | Session: Melanoma/Skin Cancers  Type: POSTER SESSION  Time: Mon, Jun 04, 1:15-4:45 PM  Location: Hall A |
| S1613 | A Randomized Phase II Study of Trastuzumab and Pertuzumab (TP) Compared to Cetuximab and Irinotecan (CETIRI) in Advanced/Metastatic Colorectal Cancer (mCRC) with HER2 Amplification: SWOG S1613.  <http://abstracts.asco.org/214/AbstView_214_220779.html> | Kanwal Raghav, Shannon McDonough, Benjamin Tan, Jr., Crystal S. Denlinger, Anthony Magliocco, Nicholas Choong, Nicolas Sommer, Frank Scappaticci, Danae Campos, Katherine A. Guthrie, Scott Kopetz, Marwan Fakih, Howard S. Hochster | Poster Board: #426a • Abstract TPS9603 | Session: Melanoma/Skin Cancers  Type: POSTER SESSION  Time: Mon, Jun 04, 1:15-4:45 PM  Location: Hall A |
| S1616 | Clinical Trial in Progress: Combining ipilimumab (ipi) and nivolumab (nivo) in advanced melanoma following progression on a PD-1 inhibitor (SWOG S1616).  <http://abstracts.asco.org/214/AbstView_214_218525.html> | A VanderWalde, M Latkovic-Taber, S Hu-Lieskovan, K Grossmann, J Sosman, D Campos, M Wu, A Ribas | Poster Board: #423a • Abstract TPS9597 | Session: Melanoma/Skin Cancers  Type: POSTER SESSION  Time: Mon, Jun 04, 1:15-4:45 PM  Location: Hall A |
| S9217 | Case-only analyses for identifying genotypes that modify the effect of finasteride in the Prostate Cancer Prevention Trial (PCPT): SWOG S9217.  <http://abstracts.asco.org/214/AbstView_214_223897.html> | James Y. Dai, Michael LeBlanc, Phyllis J. Goodman, M. Scott Lucia, Ian M. Thompson Jr, Catherine M. Tangen | Poster Board: #122 • Abstract 1551 | Session: Cancer Prevention, Hereditary Genetics, and Epidemiology  Type: POSTER SESSION  Time: Sat, Jun 02, 1:15-4:45 PM  Location: Hall A |
| Multiple | Geographic distribution and survival outcomes for rural cancer patients treated in clinical trials.  <http://abstracts.asco.org/214/AbstView_214_228067.html> | Joseph M. Unger, Anna Moseley, Banu Symington, Mariana Chavez-MacGregor, Scott David Ramsey, Dawn L. Hershman | Poster Board: #395 • Abstract 6569 | Session: Health Services Research, Clinical Informatics, and Quality of Care  Type: POSTER SESSION  Time: Sat, Jun 02, 1:15-4:45 PM  Location: Hall A |
| Multiple | Patient Comorbid Conditions and Cancer Clinical Trial Participation.  <http://abstracts.asco.org/214/AbstView_214_225271.html> | Joseph M. Unger, Dawn L. Hershman, Mark Fleury, Riha Vaidya | Poster Board: #366 • Abstract 6540 | Session: Health Services Research, Clinical Informatics, and Quality of Care  Type: POSTER SESSION  Time: Sat, Jun 02, 1:15-4:45 PM  Location: Hall A |
| **SWOG CO-LED STUDIES** | | | | |
| C/S 80405 | Causal modeling of CALGB 80405 identifies network drivers of metastatic colorectal cancer (CRC).  <http://abstracts.asco.org/214/AbstView_214_221911.html> | Rahul K. Das, Heinz-Josef Lenz, Jeffrey Meyerhardt, Donna Niedzwiecki, Andrew Nixon, Eileen O’Reilly, Fang-Shu Ou, Alan Venook, Leon Furchtgott, Daniel Cunha, Kelly Rich, Jeanne Latourelle, Diane Wuest, Boris Hayete, Iya Khalil, Federico Innocenti | Poster Board: #63 • Abstract 3570 | Session: Gastrointestinal (Colorectal) Cancer  Type: POSTER SESSION  Time: Sun, Jun 03, 8- 11:30 AM  Sun, Jun 03, 8-11:30 AM  Location: Hall A |
| C/S 80702 | Effect of age, gender, and performance status (PS) on the duration results of adjuvant chemotherapy for stage III colon cancer: The IDEA collaboration.  <http://abstracts.asco.org/214/AbstView_214_220369.html> | Anthony Shields, Fang-Shu Ou, James Paul, Alberto F. Sobrero, Takayuki Yoshino, Julien Taieb, Ioannis Souglakos, Qian Shi, Rachel Kerr, Roberto Labianca, Takeharu Yamanaka, Dewi Vernerey, Ioannis Boukovinas,Takeshi Kato, Valter Torri, Stylianos Kakolyris, Thierry Andre, Axel Grothey, Jeffrey A. Meyerhardt, Timothy Iveson | Poster Board: #92 • Abstract 3599 | Session: Gastrointestinal (Colorectal) Cancer  Type: POSTER SESSION  Time: Sun, Jun 03, 8-11:30 AM  Location: Hall A |
| S1610/  NRG- GI004 | Colorectal Cancer Metastatic dMMR Immuno-Therapy (COMMIT) Study (NRG-GI004/SWOG-S1610): A Randomized Phase III Study ofmFOLFOX6/ bevacizu-mab Combination Chemotherapy with or without Atezolizumab or Atezolizumab Monotherapy in the First-line Treatment of Patients with Deficient DNA Mismatch Repair (dMMR) Metastatic Colorectal Cancer.  <http://abstracts.asco.org/214/AbstView_214_216603.html> | James J. Lee, Greg Yothers, Samuel A. Jacobs, Hanna K. Sanoff, Deirdre J. Cohen, Katherine A. Guthrie, Norah L. Henry, Patricia A. Ganz , Scott Kopetz, Peter C. Lucas, Carmen J. Allegra, Charles D. Blanke, Norman Wolmark, Howard S. Hochster, Thomas J. George Jr., Michael J. Overman | Poster Board: #108a • Abstract TPS3615 | Session: Gastrointestinal (Colorectal) Cancer  Type: POSTER SESSION  Time: Sun, Jun 03, 8-11:30 AM  Location: Hall A |
| **OTHER GROUP-LED** | | | | |
| A091105 | Phase III, randomized, double blind, placebo-controlled trial of sorafenib in desmoid tumors (Alliance A091105).  <http://abstracts.asco.org/214/AbstView_214_210147.html> | Mrinal M. Gounder, Michelle R. Mahoney, Brian Andrew Van Tine, Vinod Ravi, Steven Attia, Hari Anant Deshpande, Abha A. Gupta, Mohammed M. Milhem, Robert Martin Conry, Sujana Movva, Michael J. Pishvaian, Jeffrey Crawford, Tarek Sabagh, Robert G. Maki, William D. Tap, Robert A Lefkowitz, Narasimhan P Agaram, John Joseph Wright, Amylou C. Dueck, Gary K. Schwartz. | Abstract 11500 | Session: Sarcoma  Type: ORAL ABSTRACT SESSION  Time: Mon, Jun 04, 8-8:12 AM  Location: S100a |
| A091605 | A Randomized Phase II Study of Anti-Pd1 Antibody [Mk-3475 (Pembrolizumab)] Alone Versus Anti-Pd1 Antibody plus Stereotactic Body Radiation Therapy in Advanced Merkel Cell Carcinoma (Alliance A091605).  <http://abstracts.asco.org/214/AbstView_214_216845.html> | Jason Luke, Steven Chmura, Joseph Salama, Hania Al-Hallaq, Charles Hsu, Sue Yom, Mark Kozloff, Jacob Allred, Pamela Munster, Gary Schwartz | Poster Board: #424a • Abstract TPS9599 | Session: Melanoma/Skin Cancers  Type:  Time: Mon, Jun 04, 1:15-4:45 PM  Location: Hall A |
| CCTG MA.32 | CA15-3/MUC1 in CCTG MA-32 (NCT01101438): A phase III RCT of the effect of metformin vs. placebo on invasive disease free and overall survival in early stage breast cancer (BC) | Ryan JO Dowling, Wendy R. Parulekar, Karen A. Gelmon, Lois E. Shepherd, Shakeel Virk, Marguerite Ennis, Fangya Mao, Jennifer A. Ligibel, Dawn L. Hershman, Priya Rastogi, Ingrid A. Mayer, Timothy J. Hobday, Julie Lemieux, Alastair Mark Thompson, Manuela Rabaglio-Poretti, Timothy Joseph Whelan, Vuk Stambolic, Bingshu E. Chen, Pamela Jean Goodwin | Abtract 557 | Session: Breast Cancer—Local/Regional/Adjuvant  Type: POSTER SESSION  Time: Sat, June 02, 8-11:30 AM  Location: Hall A |
| C80802 | Platelet count at baseline (Plt) and outcomes in patients (pts) with advanced hepatocellular carcinoma (HCC) treated with sorafenib (S) in CALGB80802 (Alliance) (C8).  <http://abstracts.asco.org/214/AbstView_214_216837.html> | Ghassan K. Abou-Alfa, Qian Shi, Jennifer J. Knox, Andreas Kaubisch, James Posey, Benjamin R. Tan Jr., Petr Kavan, Rakesh Goel, Philip E. Lammers, Tanios S. Bekaii-Saab, Vincent Channing Tam, Lakshmi Rajdev, Robin Kate Kelley, Abby B. Siegel, Tyler Zemla, Imane El Dika, Alan P. Venook, Monica M. Bertagnolli, Jeffrey Meyerhardt, Eileen M. O’Reilly | Print Only | Session: n/a  Type: n/a  Time:n/a |
| EA8143 | PROSPER: A phase III randomized study comparing perioperative nivolumab (nivo) vs. observation in patients with localized renal cell carcinoma (RCC) undergoing nephrectomy (ECOG-ACRIN 8143).  <http://abstracts.asco.org/214/AbstView_214_212011.html> | LC Harshman, M Puligandla, NB Haas, M Allaf, CG Drake, DF McDermott, S Signoretti, D Cella, RT Gupta, R Satish Bhatt, E Mendel Van Allen, TK Choueiri, P Lara, A Kapoor, D Yick C Heng, BM Shuch, MAS Jewett, DJ George, M Dror Michaelson, MA Carducci | Poster Board: #417b • Abstract TPS4597 | Session: Genitourinary (Nonprostate) Cancer  Type: POSTER SESSION  Time: Sat, Jun 02, 8-11:30 AM  Location: Hall A |
| E2211 | A Randomized Study of Temozolomide or Temozolomide and Capecitabine in with Advanced Pancreatic Neuroendocrine Tumors: A Trial of the ECOG-ACRIN Cancer Research Group (E2211).  <http://abstracts.asco.org/214/AbstView_214_231377.html> | Pamela L. Kunz, Paul J. Catalano, Halla S. Nimeiri, George A. Fisher, Jr., Teri Longacre, Carlos Suarez, James C. Yao, Matthew Kulke, Andrew Hendifar, James Shanks, Manisha Shah, Mark Zalupski, Edmond Schmulbach, Diane L. Reidy-Lagunes, Jonathan R. Strosberg, Peter J. O’Dwyer, Al B. Benson, III | Abstract 4004 | Session: Gastrointestinal (Noncolorectal) Cancer  Type: ORAL ABSTRACT SESSION  Time: 4:12 - 4:24 PM  Location: Arie Crown Theatre |
| E3805 | CHAARTED: ChemoHormonal Therapy versus Androgen Ablation Randomized Trial for Extensive Disease in Prostate Cancer: A trial of the ECOG-ACRIN Cancer Research Group (E3805).  <http://abstracts.asco.org/214/AbstView_214_225607.html> | AH Bryce, Y Chen, G Liu, MA Carducci, DF Jarrard , JA Garcia, R Dreicer, MH Hussain, MA Eisenberger, M Kohli, NM Hahn, ER Plimack, NJ Vogelzang, J Picus, RS DiPaola, LC Harshman, CJ Sweeney | Poster Board: #273 • Abstract 5046 | Session: Genitourinary (Prostate) Cancer  Type: POSTER SESSION  Time: Sat, Jun 02, 1:15- 4:45 PM  Location: Hall A |
| E7208 | Randomized trial of Irinotecan and Cetuximab (IC) versus Irinotecan, Cetuximab and Ramucirumab (ICR) as 2nd line therapy of advanced colorectal cancer (CRC) following Oxaliplatin and Bevacizumab based therapy: Results of E7208.  <http://abstracts.asco.org/214/AbstView_214_223079.html> | Howard Hochster, Paul Catalano, Edith P. Mitchell, Deirdre J. Cohen, Peter J. O'Dywer, Bryan A. Faller, Jeremy S. Kortmansky, Mark H. O'Hara, Sheetal M. Kircher, Jill Lacy, Heinz-Josef Lenz, Udit Verma, Al B. Benson, III | Abstract 3504 | Session: Gastrointestinal (Colorectal) Cancer  Type: ORAL ABSTRACT SESSION  Time: 11:15 - 11:27 AM  Location: Hall D1 |
| ECOG PACCT | TAILORx: Phase III trial of chemoendocrine therapy versus endocrine therapy alone in hormone receptor-positive, HER2-negative, node negative breast cancer and an intermediate prognosis 21-gene recurrence score.  <http://abstracts.asco.org/214/AbstView_214_212997.html> | Joseph A. Sparano, Robert James Gray, William C. Wood, Della Makower, Tracy G. Lively, Thomas James Saphner, Maccon M. Keane, Henry Leonidas Gomez, Pavan S. Reddy, Timothy F Goggins, Ingrid A. Mayer, Deborah Toppmeyer, Adam Brufsky, Matthew P. Goetz, Kathy S. Albain, Daniel F. Hayes, Elizabeth Claire Dees, Kathleen I. Pritchard, Charles E. Geyer Jr., John A. Olson, George W. Sledge Jr | Abstract LBA1 | Session: Plenary Session Including the Science of Oncology Award and Lecture  Type: Plenary Session  Time: 1:45 - 2:00 PM  Location: Hall B1 |
| Multiple NRG/  GOG | Characterization and predictors of long term (≥ 10 years) survivors in NRG/GOG randomized clinical trials of intraperitoneal and intravenous chemotherapy in stage III ovarian cancer patients.  <http://abstracts.asco.org/214/AbstView_214_222533.html> | M Friedlander, J Chan, J Java, DK Armstrong, M Markman, T Herzog , BJ Monk, F Backes, A Secord, A Bonebrake, P Rose, K Tewari, RS Mannel, S Lentz, MA Geller, LJ Copeland | Poster Board: #283 • Abstract 5556 | Session: Gynecologic Cancer  Type: POSTER SESSION  Time: Mon, Jun 04, 1:15 - 4:45 PM  Location: Hall A |
| Multiple | Association of sex and adverse events (AEs) of adjuvant chemotherapy (ACT) in early stage colon cancer (CC): A pooled analysis of 28,636 patients (pts) in the ACCENT database.  <http://abstracts.asco.org/214/AbstView_214_217297.html> | Anna Dorothea Wagner, Axel Grothey, Thierry Andre, Jesse Dixon, Norman Wolmark, Daniel G. Haller, Carmen Joseph Allegra, Eric VanCutsem, Thomas J. George, Aimery De Gramont, Steven R. Alberts, Chris Twelves, Michael O'Connell, Leonard B. Saltz, Charles David Blanke, Guido Francini, Rachel Kerr, Richard M. Goldberg, Greg Yothers, Qian Shi | Poster Board:  #96) •  Abstract:  3603 | Session: Gastrointestinal (Colorectal) Cancer  Type: Poster Session  Time: Sunday June 3, 8- 11:30 AM  Location: Hall A |